Drug Trial Radar · NCT00422240
Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris
Last checked: Nov 19, 2026Latest source record: Apr 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,668
Actual
Start
Jun 27, 2006
Primary completion
Jul 12, 2007
Study completion Jul 12, 2007
Sponsor
- Lead sponsor
- Galderma R&DIndustry
- Sponsor type
- Industry
- First posted
- Jan 15, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a multi-center, randomized, double-blind, parallel group study with 12 weeks of treatment of acne vulgaris. Efficacy and safety evaluations were performed at Screening (safety only), Baseline and Weeks 1, 2, 4, 8 and 12. All Investigator's Global Assessment evaluators and lesion counters must be trained and approved by Galderma. The evaluator of a participant should remain the same during the study. The primary objective was to demonstrate the superiority in efficacy and assess safety of adapalene/benzoyl peroxide topical gel (adapalene/benzoyl peroxide gel) versus adapalene topical gel, 0.1% (adapalene monad); benzoyl peroxide topical gel, 2.5% (benzoyl peroxide monad) and topical gel vehicle (gel vehicle) in the treatment of acne vulgaris for up to 12 weeks.
Conditions
- Acne Vulgaris
Interventions
Adapalene/Benzoyl PeroxideDrug
Adapalene 0.1 % \[weight by weight (W/W)\]/benzoyl peroxide 2.5 % (W/W) gel topically daily in the evening for 12 Weeks.
Adapalene Gel, 0.1%Drug
0.1% of adapalene gel topically daily in the evening for 12 Weeks.
Benzoyl Peroxide Gel 2.5%Drug
2.5% of benzoyl peroxide gel topically daily in the evening for 12 Weeks.
Gel VehicleDrug
Participants were treated with gel vehicle topically daily in the evening for 12 Weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Achieved Success Rate 0 (Clear) or 1 (Almost Clear) on the Investigator Global Assessment (IGA) Scale at Week 12 (Last Observation Carried Forward)Time frame: At Week 12
- Change in Inflammatory Lesion Count From Baseline to Week 12Time frame: Baseline to Week 12
- Change in Noninflammatory Lesion Count From Baseline to Week 12Time frame: Baseline to Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Miller MD
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.